[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dyslipidemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dyslipidemia":673},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,45,73,103,133,158,170,189,213,234,256,284,313,338,363,400,429,462,489,512,545,572,596,624,651],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053223",false,"NCT06980428","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia","A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4954 Following Single and Multiple Ascending Dose Administration to Healthy Participants With or Without Elevated Lp(a) Levels, and Participants With Dyslipidemia","Inclusion Criteria:\n\nAll Parts:\n\n* Participants with plasminogen level (concentration) within normal range at the Screening Visit.\n* All females must have a negative pregnancy test at the Screening Visit and on admission to the study site.\n* Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.\n* Females of non-childbearing potential must be confirmed at the Screening Visit.\n* Sexually active fertile male participants with partners of childbearing potential must adhere to the study specific contraception methods from the time of first administration of study intervention until 3 months after the study Follow-up Visit.\n\nParts A and B (Healthy Participants):\n\n* Male and female participants aged 18 to 65 years with suitable veins for cannulation or repeated venipuncture.\n* Have a body mass index (BMI) between 18 and 35 kg\u002Fm² inclusive.\n* For Japanese and Chinese participants (Parts A and B):\n\n  1. A Japanese participant is defined as having both parents and 4 grandparents who are ethnically Japanese. This includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan.\n  2. A Chinese participant is defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.\n\n     Part B (Healthy Participants):\n* Participants must have elevated Lp(a) ≥ 30 mg\u002FdL at the Screening Visit.\n\nPart B (Participants with Dyslipidemia):\n\n* Male and female participants aged 18 to 70 years with suitable veins for cannulation or repeated venipuncture.\n* Have a BMI \\> 18 kg\u002Fm².\n* Participants must have elevated Lp(a) ≥ 70 mg\u002FdL at the Screening Visit.\n* Participants with a fasting LDL-C ≥ 70 mg\u002FdL and \\\u003C 190 mg\u002FL at the Screening Visit.\n* Participants should be receiving moderate or high-intensity statin therapy for ≥ 2 months prior to the Screening Visit, according to the American College of Cardiology\u002FAmerican Heart Association guidelines on blood cholesterol management.\n* Participants with documented coronary artery disease, stroke, or peripheral artery disease or at moderate or high risk for an atherosclerotic cardiovascular disease event.\n* There should be no planned medication or dose change during study participation.\n\nExclusion Criteria:\n\nAll Parts:\n\n* History of any clinically important disease or disorder.\n* History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Any clinically important illness, medical\u002Fsurgical procedure, or trauma within 4 weeks of the first administration of study intervention.\n* Participants with known bleeding or coagulation disorders.\n* Participants who have an elevated high-sensitivity C-reactive protein (\\> 3 mg\u002FL) or have a prothrombin time\u002Finternational normalized ratio (PT\u002FINR) or activated partial thromboplastin time (aPTT) \\> 1.25 times × upper limit normal (ULN).\n* Any clinically important abnormalities in hematology, coagulation, clinical chemistry, urinalysis, abnormal vital signs or abnormal laboratory values.\n* Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG) at Screening.\n* Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.\n\nParts A and B (Healthy Participants):\n\n* Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol\u002Facetaminophen), herbal remedies, intake of \\> 3 × daily recommended levels of vitamins and minerals during the 2 weeks prior to the first administration of study intervention or longer if the medication has a long half-life.\n* Current smokers or those who have smoked or used nicotine products.\n\nPart B (Participants with Dyslipidemia):\n\n* Acute ischemic cardiovascular event in the last 12 months prior to randomization.\n* Poorly controlled diabetes.\n* Previous administration of Lp(a) inhibitor.\n* Have uncontrolled hypertension.\n* Abnormal vital heart rate.","ALL","18 Years","70 Years",{"count":20,"type":21},136,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp\\[a\\]) levels and participants with dyslipidemia.",[27,28],"Healthy Participants","Dyslipidemia",[30,31],"Lipoprotein(a)","Low-density lipoprotein cholesterol (LDL-C)","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2025-05-27",{"date":40,"type":21},"2026-12-04",{"name":42,"class":43},"AstraZeneca","INDUSTRY",6,{"id":46,"slug":4,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100053559","NCT07696403","Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose","Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose: A 12-Week Randomized Controlled Trial","Inclusion Criteria:\n\n* 25-75 year-old men and women at increased risk for cardiovascular disease. Increased risk for cardiovascular disease will be defined by either elevated cholesterol profiles -or- overweight\u002Fobesity.\n* Elevated cholesterol profiles will be defined as:\n* \"Borderline High\" and\u002For \"at risk\" in two or more of the following variables (total cholesterol: 180-239 mg\u002FdL, LDL cholesterol 110-159 mg\u002FdL, triglycerides 130-199 mg\u002FdL) --or-- \"High\" in total cholesterol (240 mg\u002FdL and higher), LDL (160 mg\u002FdL or higher), or triglycerides (between 200-350 mg\u002FdL).\n* Overweight\u002Fobesity will be defined by body mass index (overweight \\> 28 kg\u002Fm2 or obesity 30 kg\u002Fm2 or greater).\n\nExclusion Criteria:\n\n* Probable familial hypercholesterolemia, defined by: total cholesterol greater than 290 mg\u002FdL or LDL levels greater than 190 mg\u002FdL plus a family history of myocardial infarction (MI) before 50 years of age in a 2nd-degree relative or below age 60 in a 1st-degree relative.\n* Women on hormone replacement therapy less than 2 years.\n* Women who are pregnant or nursing\n* Individuals who regularly exercise more than 3h\u002Fw\n* Weight gain or loss of more than 5% body weight in the past 3 months\n* Plans to begin a weight loss\u002Fexercise regimen during the trial\n* History of medical or surgical events that could affect digestion or swallowing\n* Gastrointestinal surgeries, conditions, or disorders\n* Any chronic diseases (including moderate to severe asthma, chronic lung disease, and kidney disease)\n* Metabolic disease\n* Atherosclerosis\n* Previous MI or stroke\n* Cancer\n* Fasting blood glucose levels greater than 126 mg\u002FdL\n* Blood pressure greater than 180\u002F120 mmHg\n* Medication use affecting digestion, absorption, or metabolism (e.g. thyroid meds), lipid-lowering medications, medications for diabetes, steroid\u002Fhormone therapies, or current antibiotic cycles\n* Medically prescribed or special diets\n* Food allergies (specific to the foods in the study, including tree nuts, dairy, gluten, palm oil, and coconut oil)\n* Fish oil supplements\n* Individuals who regularly consume nuts and\u002For nut butter (defined as consumption of \\>2 servings (\\~56g) of tree nuts, nuts, or nut butter (e.g., peanut butter, almond butter) per week\n* Excessive alcohol use (greater than 3 drinks\u002Fday for men; greater than 2 drinks\u002Fday for women)\n* Tobacco or nicotine use\n* Underweight BMI (\\\u003C18.5 kg\u002Fm²)",true,"25 Years","75 Years",{"count":55,"type":21},90,[57],"NA","Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden. The bioactive compounds contained in tree nuts have been shown to beneficially affect cardiometabolic health outcomes. Pecans contain more total phenols, sterols, and flavonoids than any other tree nut. They also are a rich source of polyunsaturated fatty acids (PUFAs), fiber, vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, and zinc. These bioactive components in pecans are likely the reason for the previously documented improvements in cardiometabolic health. This study aims to examine the impact of a low dose of pecans on changes in fasting and postprandial lipid metabolism\u002Fblood lipids and markers of chronic disease risk.\n\nThe specific aims of this study are to:\n\n* Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on fasting and postprandial blood lipids.\n* Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on other markers of chronic disease risk.\n\nParticipants will be asked to:\n\n* Consume pecans daily for 12 weeks or maintain their current habitual diet.\n* Attend two short visits at 4 and 8 weeks for fasting blood draws, body measurements, and to collect their next 4 weeks' supply of study materials.\n* Attend two longer (5 h) testing visits, which include eating a standard breakfast meal and having their blood drawn periodically before and after breakfast.\n\nResearchers will compare the Pecan and Control groups to examine the physiologic effects of incorporating a low dose of pecans into one's diet.",[60,28,61],"Nutrition, Healthy","Overweight and Obesity","NOT_YET_RECRUITING","2026-07-09",{"date":35,"type":36},{"date":66,"type":21},"2026-08",{"date":68,"type":21},"2029-07",{"name":70,"class":71},"University of Georgia","OTHER",1,{"id":74,"slug":4,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":53,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100645080","NCT07679828","Polypills Approach for Multiple Cardiovascular Risk Factors","Polypills Approach for Multiple Cardiovascular Risk Factors (PACIF) : a Multicentre, Open-label, Randomized Controlled Trial","PACIF","Inclusion Criteria:\n\n* Men or women\n* Age ≥50 years and \\\u003C75 years\n* Hypertension, defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg among participants not currently taking antihypertensive medication, or systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg among participants currently taking any antihypertensive medication\n* Dyslipidemia, defined as LDL-C ≥1.8 mmol\u002FL (70 mg\u002FdL)\n* Type 2 diabetes with HbA1c ≥6.5% and \\\u003C12%\n* Willing to participate and able to sign informed consent\n\nExclusion Criteria:\n\n* Known secondary cause of hypertension\n* Type 1 diabetes\n* Pancreatic insufficiency or diabetes secondary to pancreatitis\n* Triglycerides ≥5.65 mmol\u002FL (500 mg\u002FdL)\n* History of coronary, carotid, or cerebrovascular revascularization within the previous 12 months\n* History of myocardial infarction or stroke within the previous 6 months\n* NYHA class III-IV heart failure at entry or hospitalization for exacerbation of chronic heart failure within the previous 6 months\n* Abnormal kidney function, defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m² or dialysis\n* Abnormal liver function, defined as alanine aminotransferase or aspartate aminotransferase \\>3 times the upper limit of normal\n* Abnormal serum potassium, defined as serum potassium \\>5.5 mmol\u002FL or \\\u003C3.5 mmol\u002FL\n* Contraindication to any of the components of the polypill\n* Currently living with another PACIF participant\n* Pregnancy, currently trying to become pregnant, or of child-bearing potential and not using birth control\n* Clinical diagnosis of dementia or treatment with medications for dementia\n* History of malignancy\n* Life expectancy \\\u003C3 years\n* Currently participating in another intervention study\n* Any factors judged by the clinic team to be likely to limit adherence to interventions","50 Years",{"count":82,"type":21},8252,[57],"The Polypill Approach for Multiple Cardiovascular Risk Factors (PACIF) trial is a multicenter randomized controlled trial that will test the effectiveness and safety of a fixed-dose combination strategy for integrated management of hypertension, dyslipidemia, and diabetes among adults aged 50 to 75 years in China. The trial will evaluate whether a simplified regimen combining blood pressure-lowering, lipid-lowering, and glucose-lowering therapy improves the 10-year cardiovascular disease risk score at phase 1. Participants will be followed to determine whether the fixed-dose combination strategy reduces major cardiovascular events and cognitive function compared with usual care at phase 2.",[86,28,87],"Hypertension","Diabetes",[86,28,87,89,90,91,92,93],"Polypill","Cardiovascular disease risk","Cardiovascular Diseases","Cognitive function","Randomized controlled trial","2026-06-25",{"date":96,"type":36},"2026-07-01",{"date":96,"type":21},{"date":99,"type":21},"2030-03-01",{"name":101,"class":71},"China Medical University, China",12,{"id":104,"slug":4,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":131,"locationsCount":72},"100641620","NCT07654231","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)","RESOLVE-CKD","Inclusion Criteria:\n\n* Men and women aged 18-\\\u003C70 years of all race\u002Fethnicity groups\n* CKD stage 3 (estimated glomerular filtration rate (eGFR) \\>30 to 59 ml\u002Fmin\u002F1.73m2)\n* Urine albumin-to-creatinine ratio (uACR) ≥ 200 mg\u002Fg\n* Cardiac artery calcification (CAC) Agatston score ≥30\n* Hypertension, diabetes, dyslipidemia, or established atherosclerotic cardiovascular disease (ASCVD) (coronary artery disease (CAD), ischemic stroke, and peripheral artery disease), defined by self-report, ICD-10 codes, or the use of medications for these conditions.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Current Colchicine therapy\n* Hepatic disease\n* Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.\n* Immunosuppression\n* Current use of chemotherapy drugs or active cancer\n* Pregnancy\u002Fbreastfeeding\n* Hospitalized within the past 6 months\n* Allergic\u002Fintolerance to colchicine\n* Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir\u002Fritonavir, Saquinavir, Nelfinavir)\n* Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)\n* Human immunodeficiency virus (HIV) infection\n* Gout attack ≥ 1 time per year\n* Severe anemia (hemoglobin \\\u003C 8 g\u002Fdl for women and \\\u003C 9 g\u002Fdl for men)\n* eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2\n* uACR \\\u003C200 mg\u002Fg\n* White blood cell count (WBC) \\\u003C3.0 x109\u002FL\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 x Upper Limit of Normal (ULN)\n* Total bilirubin \\>2 x ULN\n* Glucose \\>300mg\u002Fdl\n* Uses nicotine products or other recreational drugs\n* Unable to read or speak English\n* Participant in other conflict clinical trial,\n* Unable to complete the study measurements\n* Unable to undergo to computed tomography (CT) or dual-energy X-ray absorptiometry (DXA) scans\n* Unsafe to participate in this study per investigator's judgement.","69 Years",{"count":112,"type":21},60,[114],"PHASE2","The overall objective of this pilot randomized clinical trial is to determine whether low-dose Colchicine (LoDoCo) improves vascular disease including vascular calcification, peripheral arterial disease (PAD), and chronic kidney disease-mineral and bone disorder (CKD-MBD) biomarkers in patients with chronic kidney disease (CKD) stage 3 over a 12-month intervention period, compared with usual care.\n\nSuccessful completion of this study will generate critical preliminary data to support a larger clinical trial aimed at evaluating inflammation-targeted therapies to mitigate CKD-MBD, including vascular calcification and related PAD, as well as osteoporosis, ultimately reducing cardiovascular events and mortality in patients with CKD. Additionally, this work has the potential to redefine the diagnostic framework for CKD-MBD.",[117,86,87,28,118,119],"Chronic Kidney Disease Mineral and Bone Disorder","Atherosclerotic Cardiovascular Disease (ASCVD)","Chronic Kidney Disease (Stage 3)",[121,122,123,124],"Chronic Kidney Disease","CVD","vascular calcification","Colchicine","2026-06-17",{"date":127,"type":36},"2026-06-22",{"date":96,"type":21},{"date":130,"type":21},"2027-12-31",{"name":132,"class":71},"University of Texas Southwestern Medical Center",{"id":134,"slug":4,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":72},"100633239","NCT07524101","Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD","Utilizing Lipid-lowering Therapy With Moderate-intensity Statin Plus Ezetimibe in Chronic Kidney Disease Patients With Concomitant Atherosclerotic Cardiovascular Disease: ULTRA-CKD Trial","Inclusion Criteria:\n\n1. Age 19-85 years.\n2. Chronic kidney disease stage III, IV, or V (CKD-EPI eGFR \\\u003C60 \u002F \\\u003C30 \u002F \\\u003C15 mL\u002Fmin\u002F1.73 m² or on dialysis).\n3. Established ASCVD, meeting at least one of the following:\n\n   * Prior acute coronary syndrome (myocardial infarction or unstable angina).\n   * Stable angina confirmed by imaging studies.\n   * History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting).\n   * Peripheral artery disease.\n   * Ischemic stroke or transient ischemic attack.\n\nExclusion Criteria:\n\n1. Baseline LDL cholesterol \\\u003C55 mg\u002FdL in the absence of statin therapy.\n2. Acute liver disease or persistently unexplained serum AST\u002FALT ≥2 × the upper limit of normal.\n3. Allergy or hypersensitivity to statins.\n4. Life expectancy \\\u003C1 year.\n5. Expected inability to complete at least 1 year of follow-up.\n6. Inability to read or understand the informed consent form.","19 Years","85 Years",{"count":142,"type":21},1952,[57],"The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with chronic kidney disease (CKD) and concomitant atherosclerotic cardiovascular disease (ASCVD).\n\nPatients with CKD are at very high risk for ASCVD. In this population, it is important to establish a lipid-lowering strategy that optimizes cardiovascular outcomes while ensuring long-term safety. While high-intensity statins are generally considered as initial treatment option for secondary prevention, the optimal strategy for CKD patients remains to be clinicaly defined. This study aims to evaluate whether the combination of moderate-intensity statin and ezetimibe is non-inferior to high-intensity statin monotherapy in terms of 3-year composite of major adverse cardiovascular events.",[146,147,28,148,91],"Renal Insufficiency","Atherosclerosis","Hypercholesterolemia","2026-06-11",{"date":151,"type":36},"2026-06-16",{"date":153,"type":36},"2026-05-28",{"date":155,"type":21},"2031-01-22",{"name":157,"class":71},"Yonsei University",{"id":159,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":25,"conditions":162,"keywords":163,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":168,"leadSponsor":169,"locationsCount":44},"100591438",{"count":20,"type":21},[24],[27,28],[30,31],"2026-06-02",{"date":166,"type":36},"2026-06-03",{"date":38,"type":36},{"date":40,"type":21},{"name":42,"class":43},{"id":171,"slug":4,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":51,"sex":16,"minAge":139,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":173,"conditions":179,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":72},"100639685","NCT07590167","A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 and under 65 years in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied","64 Years",{"count":112,"type":21},[24],[28,86],"2026-05-11",{"date":182,"type":36},"2026-05-15",{"date":184,"type":21},"2026-06",{"date":186,"type":21},"2026-07",{"name":188,"class":43},"Addpharma Inc.",{"id":190,"slug":4,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":196,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":72},"100619889","NCT07350486","LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia","A Cluster-Randomized Trial of Large Language Model-Enabled Coordinated Management for Hypertension, Diabetes, and Dyslipidemia in Community Settings (LLM-CoManage Trial)","LLM-CoManage","Inclusion Criteria:\n\nParticipating communities must meet all of the following criteria:\n\n* Have a designated community physician responsible for primary care who is capable of using a smartphone with stable internet access for clinical communication and LLM-assisted management;\n* No plan for administrative merger or restructuring within the next three years;\n* Located at least 2 kilometers away from adjacent participating communities (to minimize contamination between clusters).\n\nEligible participants must fulfill all of the following conditions:\n\n* Aged 40 years or older;\n* Uncontrolled hypertension, defined as systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg;\n* Coexisting diabetes (HbA1c ≥ 7.0%) or coexisting dyslipidemia (LDL-C ≥ 3.4 mmol\u002FL\\[130 mg\u002FdL\\]);\n* Able to use a smartphone independently or with assistance from family members;\n* Has resided in the participating community for at least 6 months;\n* Has no plan to relocate in the next 3 years;\n* Enrolled in basic medical insurance for urban and rural residents, employee medical insurance, or the New Rural Cooperative Medical Scheme;\n* Not currently pregnant or planning pregnancy during the study period;\n* Free from malignant tumors and deemed to have a life expectancy of at least 3 years, as judged by study physicians;\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:No specific exclusion criteria.","40 Years",{"count":198,"type":21},6800,[57],"This study aims to evaluate the effectiveness of a large language model (LLM)-supported, community-based integrated management model in improving cardiometabolic multimorbidity control among adults with hypertension and coexisting diabetes or dyslipidemia. Adopting an interventional study design, eligible patients will be recruited to compare the disease control indicators between LLM-assisted management and conventional management, so as to verify the effectiveness and safety of the former.",[86,87,28],[203,204],"Large Language Model","Co-Management","2026-05-09",{"date":207,"type":36},"2026-05-13",{"date":209,"type":21},"2026-06-15",{"date":130,"type":21},{"name":212,"class":71},"First Hospital of China Medical University",{"id":214,"slug":4,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":51,"sex":16,"minAge":139,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":72},"100638182","NCT07581028","Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-C715\" and \"C715R\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n1. Healthy adults aged 19 to less than 60 years at the time of screening\n2. Weight ≥ 50 kg for men or ≥ 45 kg for women, with a calculated body mass index(BMI) of 18 to 30 kg\u002Fm² at the time of screening.\n3. Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings.\n4. Those who are eligible for the clinical trial based on laboratory test results(hematology, blood chemistry, serum, and urine tests) and 12-lead ECG findings during screening.\n5. Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial.\n6. Those who agree to use highly effective methods of contraception(excluding hormonal methods) to prevent pregnancy, either for themselves or their spouse\u002Fpartner, from the first administration of the investigational medicinal product until one week after the last administration, and who agree not to donate sperm or eggs during this period.\n\nExclusion Criteria:\n\n1. Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days.\n2. Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug. 3. Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study.\n\n4\\. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug.\n\n5\\. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass\u002Fweek, Women - 14 glass\u002Fweek (1 glass: Soju 50 mL, Beer 250mL or liquor: 30mL), Smoke: 20 cigarettes\u002Fday.\n\n6\\. Those who has under\n\n* Those who are hypersensitive to component of the Investigational product and have the medical history\n* Those with active liver disease or persistent elevation of aminotransferase levels of unknown\n* Those taking cyclosporin\n* Those with Myopathy\n* Those with severe Renal Impairment due to Renal Failure\n* Those who has Genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption 7. Those who has a history of mental illness. 8. Those who are deemed unfit by the investigators to participate in the clinical trial for other reasons.\n\n  9\\. Women who are pregnant or who may be pregnant and breastfeed.","59 Years",{"count":112,"type":21},[24],"To Evaluate the Safety and Pharmacokinetics of \"AJU-C715\" and \"C715R\" in Healthy Adults.",[224,28],"Hypercholerolemia","2026-05-06",{"date":227,"type":36},"2026-05-12",{"date":229,"type":21},"2026-08-07",{"date":231,"type":21},"2026-08-24",{"name":233,"class":43},"AJU Pharm Co., Ltd.",{"id":235,"slug":4,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":240,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":72},"100467335","NCT05365425","Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Effect of Choline Fenofibrate on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia","Inclusion Criteria:\n\n* Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit\n* Male or female of 20 years or over\n* Mixed dyslipidemia: triglyceride 200\\~499 mg\u002FdL, HDL-cholesterol male ≤45 mg\u002FdL or female ≤50 mg\u002FdL\n* Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm\n* Creatinine ≤1.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Dyslipidemia which requires other therapy: triglyceride ≥500 mg\u002FdL or LDL-cholesterol ≥190 mg\u002FdL\n* Uncontrolled hypertension\n* Severe renal dysfunction\n* GOT\u002FGPT \\>120\u002F120 or chronic liver disease\n* Pregnant or childbearing woman who does not have enough contraception\n* Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months\n* Other antiplatlet medication such as cilostazol, clopidogrel (except aspirin)","20 Years",{"count":242,"type":21},56,[244],"PHASE4","This is a randomized controlled study to assess the effect of choline fenofibrate compared with policosanol in Korean T2DM patients with asymptomatic atherosclerosis.",[28,147,247],"Diabetes Mellitus, Type 2","2026-05-02",{"date":250,"type":36},"2026-05-05",{"date":252,"type":36},"2023-06-01",{"date":130,"type":21},{"name":255,"class":71},"Seoul National University Bundang Hospital",{"id":257,"slug":4,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":262,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":72},"100635429","NCT07552571","Goal Commitment and Proactive Health Behavior in Chronic Disease Patients","Evolution and Driving Mechanism of Proactive Health Behavior in Chronic Disease Patients Based on Goal Commitment","Inclusion Criteria:\n\n* Residents living in the study area for at least 1.5 years\n* Diagnosed with at least one chronic disease, including hypertension, diabetes mellitus, or dyslipidemia\n* Conscious and able to communicate effectively\n* Educational level of primary school or above\n* Able to use a smartphone and common mobile applications (e.g., WeChat)\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Non-residents of the study area\n* Unable to participate in group-based intervention activities\n* Currently hospitalized\n* Diagnosed with severe cognitive impairment, dementia, or psychiatric disorders\n* Participants with severe comorbidities that may interfere with study participation","45 Years",{"count":264,"type":21},600,[57],"Chronic diseases such as hypertension, diabetes, and dyslipidemia are major contributors to mortality and healthcare burden worldwide. Despite high awareness of health risks, many patients fail to adopt proactive health behaviors due to behavioral inertia and a gap between knowledge and action.\n\nThis study aims to investigate the evolution and driving mechanisms of proactive health behavior in patients with chronic diseases based on goal commitment theory. By integrating prospect theory and evolutionary game theory, this study will explore how behavioral strategies evolve under different levels of goal commitment.\n\nIn addition, a behavioral intervention based on the Stimulus-Organism-Response (SOR) model will be developed to enhance patient activation and promote adherence to proactive health behaviors. A parallel controlled intervention study will be conducted to evaluate the effectiveness of the goal commitment-based intervention.\n\nThe findings of this study are expected to provide theoretical and practical evidence to improve chronic disease management and promote proactive health behaviors.",[86,268,28],"Diabetes Mellitus",[270,271,272,273,274,275],"Proactive Health Behavior","Goal Commitment","Chronic Disease Management","Behavioral Intervention","Patient Activation","SOR Model","2026-04-30",{"date":225,"type":36},{"date":279,"type":36},"2025-05-15",{"date":281,"type":21},"2028-12-31",{"name":283,"class":71},"Xiong Juyang",{"id":285,"slug":4,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":299,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":72},"100585860","NCT06907862","The SWITCH (Substitution of High With Low Ultra-processed Soy Protein Foods In a Guideline-based Diet inTervention for Cardiometabolic Health) Trial","SWITCH","Inclusion Criteria:\n\n* Obesity (BMI and waist circumference using sex and ethnic-specific thresholds for obesity and significant abdominal adiposity)\n* adults (≥18years)\n* hypertension (SBP 120-160 mmHg)\n* on stable antihypertensive, antihyperglycemic, antihyperlipidemic, or anti-obesity medications (≥3-months)\n* not planning new weight loss for the duration of the trial\n* 50% living with type 2 diabetes, HbA1c 6.5-9.0%\n\nExclusion Criteria:\n\n* Individuals with a history of major cardiovascular events in the last year (stroke or myocardial infarction)\n* type 1 diabetes diagnosis\n* recent weight loss or weight gain (≥5% over \\\u003C6 months)\n* current treatment with insulin\n* eating disorders; substance abuse disorders\n* serious depression or psychiatric disorders\n* bariatric or recent surgery (\\\u003C6 months)\n* uncontrolled hypertension (SBP\u002FDBP \\>160\u002F100 mmHg)\n* angina pectoris\n* gastrointestinal and malabsorption disorders (i.e. inflammatory bowel disease, celiac), pancreatitis, chronic kidney or liver disease, cardiac condition that compromises normal function (e.g. mitral valve disease, heart failure), major disability or disorder requiring continuous medical attention.\n* herb or supplement use that may affect primary outcome.\n* alcohol use \\>3 drinks\u002Fday; participation in another trial.\n* allergies\u002Fintolerances to soy; allergies\u002Fintolerances to tree nuts, peanuts and seeds (the combination of all 3).\n* chronic or prescribed use of certain medications including prescription high dose NSAIDs, antacids, warfarin, medications affecting NO synthesis (i.e. sildenafil, organic nitrates, etc.)\n* acute or chronic infection (e.g. active HIV, TB, COVID-19, chronic inflammatory infections)\n* chronic inflammatory condition (such as rheumatoid arthritis)\n* use of antibiotics within 3-months of the study start",{"count":291,"type":21},300,[57],"This is a randomized, controlled, parallel study with 3 experimental arms aimed to assess the effect of a digital dietary intervention (web-based app, online behavior change curriculum) enhanced with 10 servings of vegetables and fruit (5 as dietary advice within the app, 5 within a dehydrated vegetable and fruit blend), with or without high Ultra Processed Food (UPF) soy-containing proteins compared to standard of care (usual care) on systolic blood pressure (SBP; primary outcome), and other key cardiometabolic endpoints over 12-weeks in adults living with hypertension and obesity, 50% with type 2 diabetes. The main questions this study aims to answer are:\n\n1. Are nutrient-dense, high-UPF soy-protein foods similar (non-inferior) to low-UPF soy-protein foods in the context of a guidelines-based diet in their effect on blood pressure and other cardiometabolic risk factors?\n2. Does an enhanced digital dietary intervention lead to meaningful reductions in blood pressure and other cardiometabolic risk factors compared to standard of care?\n\nParticipants who are eligible and consent to be part of this study will be randomized to one of the following groups: 1) Active treatment (high-UPF soy-containing enhanced digital dietary intervention), 2) Reference treatment (low-UPF soy-containing enhanced digital dietary intervention), or 3) Control (standard of care).\n\nParticipant Requirements:\n\nDuring the 12-week intervention, all participants will be required to attend in-person clinic visits at baseline (week 0), week 8 and 12.\n\nBaseline Visit (Week 0): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse).\n* Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n* Bring fecal and urine samples from home.\n* Complete and review all questionnaires received via email one week prior.\n\nTelephone Check-in (Week 1):\n\nOne week after beginning the study, the study staff will call participants to check in on how participants are following the protocol and answer any questions.\n\nMid-Study Visit (Week 8): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Have their office blood pressure and anthropometric measurements taken.\n* Complete and review all questionnaires received via email one week prior\n* Review the 3-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n\nFinal Study Visit (Week 12): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).\n\n* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse).\n* Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit.\n* Bring fecal and urine samples from home.\n* Complete and review all questionnaires received via email one week prior.\n\nThroughout the study, participants will be asked to continue their usual lifestyle and physical activity.\n\nAdditional Requirements for Treatment Groups:\n\nParticipants randomized to the active and reference treatment groups will also be required to:\n\n* Incorporate a study vegetable and fruit blend (provided) into their daily diet for the full 12 weeks\n* Consume soy products categorized as either high ultra processed soy foods at least 4 servings per day, including at least 2 servings of ultra processed soy milk and 2 servings of other soy-based products (e.g., soy yogurt, soy burgers, or soy ground round) or non-ultra processed soy foods at least 4 servings per day, including at least 2 servings of minimally processed soy milk, 1 serving of edamame or roasted soy nuts, and 1 serving of tofu or tempeh\n* Participate in the digital dietary intervention, which includes: a health app, 7-day Kickstart Package, weekly text message support, and a 7-session online interactive program designed based on behaviour change theory\n* Attend a virtual focus group at Week 4 and complete an online feedback questionnaire",[295,296,28,86,297,298],"Hypertension in Type 2 Diabetes","Diabetes Mellitus Type 2","Metabolic Health","Cardiovascular Risk Factors",[93,86,300,301,302,303],"Cardiometabolic health","Ultra processed food","technology-based dietary intervention","dehydrated vegetable and fruit blend","2026-04-27",{"date":306,"type":36},"2026-05-04",{"date":308,"type":36},"2025-08-06",{"date":310,"type":21},"2028-06-30",{"name":312,"class":71},"University of Toronto",{"id":314,"slug":4,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":196,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":326,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":72},"100635932","NCT07559110","Supplementation With Salicornia Extract Rich in Polyphenols (B-Salicornia) to Improve Vascular Health in Patients With Dyslipidemia Who Are Not Candidates for Drug Treatment (Low to Moderate Risk)","Prospective, Randomized, Open-label, Parallel-Group Pilot Study Compared With Usual Medical Practice and Blinded Analysis (PROBE), to Evaluate the Effect and Safety of Administering a Food Supplement Based on Halophyte Plant Extracts in Patients With Newly Diagnosed Dyslipidemia Who do Not Have an Indication for Medical Treatment.","SALICOL","Inclusion Criteria:\n\n* Participants aged 40 to 65\n* Newly diagnosed dyslipidemia (two years) with SCORE ≥1 - \\\u003C5 (LDL 116 - \\\u003C190 mg\u002FdL): Moderate Risk\n* No indication for pharmacological treatment in primary prevention.\n* Possibility of performing analytical controls at the beginning\u002Fend of the study.\n* Willingness and capacity to give informed consent.\n\nExclusion Criteria:\n\n* Participants with vascular risk requiring pharmacological treatment or high\u002Fvery high vascular risk.\n* Participants in secondary prevention.\n* Hyperthyroidism according to the researcher's criteria.\n* Taking vitamin B supplements and\u002For supplements containing polyphenols in the 30 days prior to the screening visit (at the researcher's discretion).\n* Serious illness with a life expectancy of less than three months.\n* Known allergies or intolerance to halophytic plants.\n* Pregnant or breastfeeding women.\n* Presence of active neoplastic disease.\n* Having participated in another clinical trial with medicines in the 30 days prior to the screening visit, or intending to do so during your participation in this study.\n* Regular consumption of halophyte plants.\n* Participants who, in the researcher's opinion, are not able to comply with the study protocol.","65 Years",{"count":322,"type":21},250,[57],"The aim of this clinical trial is to evaluate the ability of a dietary supplement based on salicornia extracts and B vitamins (B-Salicornia) to modulate lipid levels in a population with newly diagnosed dyslipidemia who are not eligible for medical treatment.",[28],[327,328,329],"food supplement","polyphenol","Dyslipidaemia","2026-04-23",{"date":276,"type":36},{"date":333,"type":21},"2026-05",{"date":335,"type":21},"2027-05",{"name":337,"class":71},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla",{"id":339,"slug":4,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":343,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":72},"100634847","NCT07545005","Impact of a Produce Prescription Program and Nutrition Education Intervention on Cardiovascular Health in Youth","Inclusion Criteria:\n\n1. Ages 2-17 years (with caregiver)\n2. Patient at BCH AND\n3. Underlying cardiovascular risk condition:\n\n   1. High Blood Pressure\n   2. Dyslipidemia\n   3. Elevated BMI AND\n4. Enrolled in or eligible for a Medicaid Healthcare plan OR\n5. SNAP eligible\n\nExclusion Criteria:\n\n1\\. Conditions that require urgent treatment:\n\n1. Hypertensive Urgency\n2. Hypertensive Emergency\n3. Dialysis-dependent kidney disease","2 Years","17 Years",{"count":346,"type":21},150,[57],"This study will assess the effect of a produce prescription program combined with nutritional classes on short and longer-term cardiovascular health in a cohort of children at risk for cardiovascular disease. The communities of interest we aim to engage in this project are children and adolescents in Boston and the surrounding areas with acquired cardiovascular risk factors of high blood pressure or abnormal cholesterol that are cared for at Boston Children's Hospital and who qualify or are enrolled in (1) Benefits under the Food and Nutrition Act of 2008; (2) medical assistance under a State plan or a waiver of such a plan under title XIX of the Social Security. This project will create a first-time partnership between the BCH cardiology department and a produce prescription program (Fresh Connect) and will introduce services and resources not previously available to these patients. Participants will be able to use the Fresh Connect pre-paid debit card to purchase fruits and vegetables of their choosing from numerous local food retailers convenient to their own neighborhood. We currently do not have any healthcare-led social support networks amongst patients seen for evaluation of cardiovascular risk factors. As such, this project will introduce a new community-building resource amongst our patients by creating interactive, culturally tailored nutritional classes. The virtual nutrition classes will offer a friendly, interactive environment in which patients and families can share their experiences and learn from each other and from our dietitians. By fostering these relationships amongst patients\u002Fcaregivers, we hope to decrease the stigma some families feel when their child is diagnosed with hypertension or abnormal cholesterol.",[28,86,350],"Obesity & Overweight",[352,353],"Food insecurity","food is medicine","2026-04-16",{"date":356,"type":36},"2026-04-22",{"date":358,"type":21},"2026-06-01",{"date":360,"type":21},"2029-04-01",{"name":362,"class":71},"Boston Children's Hospital",{"id":364,"slug":4,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":370,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":376,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":396,"leadSponsor":398,"locationsCount":72},"100632583","NCT07515573","Effect of Compound (Cardiol Forte) on Lipid And Glycemic Parameters in Low Cardiovascular Risk Individuals","A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group Clinical Trial With an Open-Label Extension to Evaluate the Effects of a Combination Dietary Supplement (Cardiol Forte) on Lipid and Glycemic Parameters in Subjects at Low Cardiovascular Risk With Suboptimal Cholesterol Levels","CLARISKI","Inclusion Criteria:\n\n* Male or female aged 18 to 79 years\n* Individuals in primary cardiovascular prevention\n* Estimated 10-year cardiovascular risk \\\u003C10%\n* Screening non-HDL-C between 140 and 220 mg\u002FdL, or screening LDL-C between 110 and 190 mg\u002FdL\n* Ability to communicate adequately, to be understood, and to comply with the study requirements\n* Willingness to participate in the study and provision of written, signed, and dated informed consent\n\nExclusion Criteria:\n\n* Triglycerides \\>400 mg\u002FdL at screening\n* Type 1 or type 2 diabetes mellitus\n* Body mass index \\>35 kg\u002Fm²\n* Current treatment with lipid-lowering drugs or use of dietary supplements active on lipid metabolism\n* Antihypertensive treatment not stabilized for at least 3 months\n* Known clinically significant alterations of thyroid, hepatic, and\u002For renal function\n* Women of childbearing potential not using adequate contraceptive methods\n* Pregnancy or breastfeeding\n* Any medical or surgical condition that, in the investigator's judgment, could make adherence to the protocol difficult or inconsistent, compromise participant safety, or interfere with study completion\n* Known intolerance or hypersensitivity to any component of the study products","79 Years",{"count":372,"type":21},50,[57],"This study will evaluate the effects of a combination dietary supplement, Cardiol Forte, on lipid and glycemic parameters in adults at low cardiovascular risk with suboptimal cholesterol levels. After a 14- to 28-day run-in period with standardized dietary and behavioral instructions, 50 participants will be randomized in a 1:1 ratio to receive either Cardiol Forte or matching placebo for 8 weeks under double-blind conditions. After completion of the double-blind phase, all participants will receive Cardiol Forte for an additional 8 weeks in an open-label extension. The primary objective is to compare the change in non-high-density lipoprotein cholesterol (non-HDL-C) from baseline to Week 8 between Cardiol Forte and placebo. Secondary objectives include evaluation of other lipid parameters, fasting plasma glucose, Omega-3 Index, selected inflammatory and liver-related markers, and endothelial reactivity.",[28],[377,28,378,379,380,381,382,383,384,385,386,387,388,389,390,391],"Cardiol Forte","non-HDL cholesterol","Glycemic profile","Cardiovascular prevention","Low cardiovascular risk","Eicosapentaenoic acid","EPA","Docosahexaenoic acid","DHA","Artichoke","Bergamot","Hydroxytyrosol","Coenzyme Q10","Folic acid","Vitamin E","2026-04-15",{"date":394,"type":36},"2026-04-20",{"date":306,"type":21},{"date":397,"type":21},"2028-05-04",{"name":399,"class":43},"U.G.A. Nutraceuticals",{"id":401,"slug":4,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":51,"sex":16,"minAge":406,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":408,"phases":4,"briefSummary":409,"conditions":410,"keywords":415,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":425,"leadSponsor":427,"locationsCount":72},"100631593","NCT07502703","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community-Based Population in Semanan, Jakarta","Inclusion Criteria:\n\n1. Adults aged ≥30 years\n2. Willing to participate and provide informed consent\n3. Able to undergo face scan, clinical examination, and laboratory testing\n\nExclusion Criteria:\n\n1. Facial abnormalities interfering with rPPG signal acquisition\n2. Inability to remain still during measurement\n3. Severe clinical instability\n4. Incomplete key variables","30 Years",{"count":291,"type":21},"OBSERVATIONAL","The goal of this observational study is to evaluate whether a contactless camera-based technology, called remote photoplethysmography (rPPG), can accurately measure cardiovascular parameters and estimate cardiovascular risk in adults aged 30 years and older living in a community setting in Semanan, Jakarta. This study aims to determine if rPPG can be used as a simple and accessible tool for early cardiovascular screening.\n\nThe main questions it aims to answer are:\n\n1. Do cardiovascular parameters measured using rPPG (such as blood pressure, heart rate, and cardiac workload) agree with standard clinical measurements?\n2. Do cardiovascular risk estimates generated by rPPG (such as ASCVD risk and Framingham heart age) correspond to risk calculations obtained using conventional clinical and laboratory methods?\n\nResearchers will compare results obtained from rPPG-based facial video scans with results from standard medical assessments, including blood pressure measurements, heart rate evaluation, and laboratory tests for cholesterol levels, to determine the level of agreement and accuracy.\n\nParticipants will:\n\n1. Undergo a short facial video scan (approximately 30-60 seconds) using an rPPG-based system\n2. Receive standard clinical assessments, including blood pressure and heart rate measurements\n3. Provide basic health information (such as age, sex, smoking status, and treatment history) Undergo simple laboratory testing for cholesterol levels\n\nThis study is expected to help determine whether rPPG can be used as a reliable, non-invasive, and scalable screening tool for cardiovascular risk in community and primary healthcare settings.",[28,411,412,413,86,414],"Angina (Stable)","Coronary Artery Disease (CAD)","Heart Disease","Diabetes (DM)",[416,417,418,419,420,421,422],"remote photoplethysmography","rPPG","cardiovascular risk","ASCVD","Framingham score","digital health","screening tool",{"date":394,"type":36},{"date":330,"type":21},{"date":426,"type":21},"2026-12-30",{"name":428,"class":71},"Tarumanagara University",{"id":430,"slug":4,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":176,"enrollmentInfo":436,"targetDuration":4,"studyType":22,"phases":438,"briefSummary":439,"conditions":440,"keywords":443,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":461},"100611282","NCT07238556","A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors","Feasibility and Acceptability of a Novel Algorithm for Physicians to Prescribe Personalized Exercise Prescriptions to Patients With Cardiovascular Disease Risk Factors: Study Protocol for an Exploratory Randomized Controlled Crossover Trial","P3-EX","Physician Inclusion Criteria\n\n1. Practicing medical doctors employed at the study recruitment sites\n2. Do not recommend written exercise programs or plans to their patients, nor refer them to exercise clinics or exercise professionals\n3. Are willing to recruit two of their patients to deliver Prioritize Personalize Prescribe EXercise (P3-EX) and American College of Sports Medicine Physical Activity Vital Sign (ACSM PAVS)\n\nPatient Inclusion Criteria\n\n1. Sedentary: have not performed planned, structured physical activity at moderate intensity for ≥30 minutes on ≥3 days per week in the last 3 months\n2. Adults: ≥18 and ≤64 yrs\n3. ≥1 cardiovascular disease risk factors: Having obesity, hypertension, dyslipidemia, and\u002For diabetes (or prediabetes)\n\n   * Obesity: BMI ≥30 kg\u002Fm2 or WC \\>102 cm (40 in) for men and \\>88 cm (35 in) for women\n   * Hypertension: Systolic BP ≥130 mm Hg and\u002For diastolic BP ≥80 mm Hg, or on antihypertensive medication\n   * Dyslipidemia: LDL-C ≥130 mg\u002FdL (3.37 mmol\u002FL), or HDL-C \\\u003C40 mg\u002FdL (1.04 mmol\u002FL) in men and \\\u003C50 mg\u002FdL (1.3 mmol\u002FL) in women, or non-HDL-C ≥160 mg\u002FdL (4.14 mmol\u002FL), or on lipid-lowering medication, or TC ≥200 mg\u002FdL (5.18 mmol\u002FL)\n   * Diabetes (or prediabetes): FBG ≥100 mg\u002FdL or HbA1c ≥5.7%, or on medication for diabetes\n4. Healthy: Having no signs or symptoms of or have cardiovascular or renal disease, or other diseases or health conditions that significantly limit physical activity engagement\n5. Not pregnant or lactating\n6. Not a cigarette smoker or quit smoking ≥6 months ago\n7. Consume \\\u003C2 alcoholic drinks daily\n8. Able to use a computer or phone with internet access\n9. Fluent in English\n10. Willing to maintain their medication routine and habitual diet and not follow other exercise or nutrition programs.\n\nPatient Exclusion Criteria 4a. Have pain or discomfort in the chest, neck, jaw, or arms; dizziness or syncope; shortness of breath at rest or with mild exertion; unusual fatigue or shortness of breath with usual activities; orthopnea; ankle edema; intermittent claudication; palpitations; or known heart murmur 4b. Stroke or cancer survivors or currently have cancer, chronic obstructive pulmonary disease, musculoskeletal injury, chronic back pain, depression, dementia, or other diseases or health conditions that are deemed to significantly limit physical activity engagement.",{"count":437,"type":21},72,[57],"The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.",[86,28,268,441,442],"Obesity","Cardiovascular Disease",[444,445,446,447,448,449,450,451,452],"Exercise prescription","Exercise Therapy","Physical Activity","Preventive Health Services","Health Behavior","Medical Informatics Applications","Health technology","Precision Medicine","Primary Health Care","2026-04-14",{"date":392,"type":36},{"date":456,"type":36},"2026-03-30",{"date":458,"type":21},"2026-05-31",{"name":460,"class":71},"University of Connecticut",3,{"id":463,"slug":4,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":475,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":487,"locationsCount":72},"100625534","NCT07423884","Effect of a Low-Calorie MCT-Rich Traditional Minangkabau Diet on Obese Individuals","The Effect of a Low-Calorie Diet Rich in Medium-Chain Triglycerides Based on Traditional Minangkabau Foods on Lipid Profile, Leptin Levels, and DNA Methylation of the Leptin Gene Promoter in Individuals With Obesity","Inclusion Criteria:\n\n* Administrative staff of the Faculty of Medicine and the Faculty of Public Health, Andalas University, Padang, with obesity defined as a body mass index (BMI) ≥ 25 kg\u002Fm².\n* Willing to participate in the study by providing written informed consent.\n* Participants with obesity classified as Metabolically Unhealthy Obese (MUHO)\n\nExclusion Criteria:\n\n* Did not come and could not be found at the time of research data collection\n* Unable to follow the dietary arrangements as set\n* Taking anti-diabetic or anti-lipid drugs\n* Use of contraceptives or hormonal drugs\n* In the treatment of radiotherapy or chemotherapyi\n* Participants with obesity classified as Metabolically Healthy Obese (MHO)",{"count":469,"type":21},40,[57],"This study aims to investigate the effect of a low-calorie diet rich in medium-chain triglycerides (MCTs) based on traditional Minangkabau foods on metabolic biomarkers in individuals with obesity. The traditional Minangkabau foods used in this study consist primarily of coconut milk-based dishes, which contain coconut oil as a natural source of MCTs. The metabolic biomarkers assessed include body mass index (BMI), waist circumference, systolic and diastolic blood pressure, body fat percentage, fasting blood glucose levels, lipid profile, leptin concentrations, and DNA methylation of the leptin gene promoter. Based on these metabolic biomarker measurements, participants will be classified into metabolic obesity phenotypes, namely metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUHO). The researchers hypothesize that the provision of a low-calorie, MCT-rich diet based on traditional Minangkabau foods will have a significant effect on metabolic biomarkers and metabolic status in individuals with obesity.",[473,28,414,474,441],"Metabolically Unhealty Obese","Resistance, Insulin",[476,477,478,479,480],"Low-calorie diet rich in medium-chain triglycerides","Traditional Minangkabau foods","Coconut oil","Metabolic biomarkers","Anthropometric parameters","2026-04-08",{"date":483,"type":36},"2026-04-13",{"date":485,"type":21},"2026-04",{"date":186,"type":21},{"name":488,"class":71},"Andalas University",{"id":490,"slug":4,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":16,"minAge":139,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":408,"phases":4,"briefSummary":497,"conditions":498,"keywords":499,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":509,"leadSponsor":510,"locationsCount":72},"100632582","NCT07515560","Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study","A Prospective, Non-interventional, Multi-center Observational Study to Evaluate the Efficacy and Safety of Baroezet Tablet 1\u002F10 mg in Korean Patients With Dyslipidemia","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Patients diagnosed with dyslipidemia\n* Patients who require treatment with Baroezet Tablet\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Hypersensitivity to study drug components\n* Active liver disease\n* Pregnant or breastfeeding women\n* Patients considered inappropriate by investigator",{"count":496,"type":21},12000,"This study is a prospective, non-interventional, multi-center observational study to evaluate the efficacy and safety of Baroezet Tablet 1\u002F10 mg in Korean patients with dyslipidemia in real-world clinical practice.\n\nPatients who are prescribed Baroezet Tablet according to the physician's clinical judgment will be followed for approximately 24 weeks. The study will assess changes in lipid profiles, including LDL-C, as well as safety outcomes such as adverse events.",[28],[28,500,501,502,503,504],"LDL-C","Statin","Ezetimibe","Observational Study","Real-world","2026-03-31",{"date":507,"type":36},"2026-04-07",{"date":276,"type":21},{"date":130,"type":21},{"name":511,"class":43},"Daewoong Pharmaceutical Co. LTD.",{"id":513,"slug":4,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":51,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":22,"phases":520,"briefSummary":521,"conditions":522,"keywords":530,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":72},"100619127","NCT07340580","Implementation Facilitation of Exercise is Medicine Greenville","Facilitating Health System Implementation of Physical Activity Screening and Referral to Community-Based Programs: Exercise is Medicine Greenville","The primary aim of this study is implementation facilitation at the clinic level. The secondary aim of this study is at the patient level. Therefore we have divided our inclusion\u002Fexclusion eligibility criteria by primary and secondary aim.\n\n1\\. Clinic (primary aim) Inclusion criteria\n\n* Currently EIMG-activated Prisma Health-Upstate Primary Care clinic (family or internal medicine)\n* Adopted EIMG \\>= 6 months prior to the beginning of this study\n\nExclusion criteria\n\n* Not EIMG-activated\n* Adopted EIMG \\\u003C 6 months prior to the beginning of this study\n* Greater than 15 miles from the nearest YMCA\n\n  1\\. Primary care clinic staff (primary aim) Inclusion criteria\n* At least 18 years of age\n* Has worked at the Prisma Health-Upstate clinic since the start date of the intervention in the respective wave, i.e., Pre-IF start date for each wave\n* Has clinical encounters with a minimum of 25 patients per month\n* Study clinic is their primary clinic (\\>50% of their working time)\n* Able to understand and communicate in English\n\nExclusion criteria\n\n* Less than 18 years of age\n* Work at the Prisma Health-Upstate clinic started after the Pre-IF phase began\n* Has clinical encounters with \\\u003C25 patients per month\n* Unable to speak or understand English\n* Adults unable to provide consent\n\n  2\\. Patient (secondary aim) Inclusion criteria (must meet all of below)\n* Age \\>= 18 and \\\u003C= 80 years\n* Clinically eligible (diagnosis of hypertension, dyslipidemia, obesity, diabetes, or physical inactivity) to receive an EIMG referral\n* A healthcare visit with an eligible encounter type (evaluation, telemedicine, consult, office visit, e-visit, follow-up, appointment, education, multidisciplinary visit, nutrition, occupational medicine-office visit)\n* A healthcare visit at a participating clinic\n\nExclusion criteria\n\n* Age \\\u003C 18 or \\> 80 years\n* Current referral to Physical therapy or occupational therapy\n* Current referral to cardiac, pulmonary, or oncology rehab\n* One of the following visit diagnoses listed below:\n\n  * Alzheimer's disease\n  * Amyotrophic lateral sclerosis\n  * angina or chest pain\n  * congenital stenosis of aortic valve\n  * congenital insufficiency of aortic valve\n  * moderate or severe persistent asthma\n  * typical or atypical atrial flutter\n  * autonomic dysreflexia\n  * acute bronchitis\n  * cerebral infarction\n  * encounter for chemotherapy\n  * chronic kidney disease (stage 3-5)\n  * end stage renal disease\n  * coma\n  * acute chronic obstructive pulmonary disease\n  * unspecified dementia\n  * dependence on renal dialysis\n  * trisomy 21\n  * pulmonary embolism\n  * venous embolism and thrombosis\n  * history of falling\n  * acute fracture\n  * left ventricular failure\n  * congestive heart failure\n  * hypertensive urgency, emergency or crisis\n  * diabetes with ketoacidosis\n  * chronic respiratory failure\n  * dependence on supplemental oxygen\n  * myocardial infarction\n  * osteoporosis with current fracture\n  * encounter for palliative care\n  * paraplegia or quadriplegia\n  * Parkinson disease\n  * pneumonia\n  * encounter for supervision of pregnancy\n  * encounter for radiation therapy\n  * serious mental illness (schizophrenia, psychotic disorder)\n  * homicidal or suicidal ideations\n  * sepsis\n  * injury of spinal cord\n  * presence of coronary stent\n  * dependence on wheelchair or ambulatory aid\n\nFor patients completing accelerometry data collection, the additional inclusion\u002Fexclusion criteria apply:\n\nInclusion criteria:\n\n* Received an EIMG referral and scheduled for orientation\n* Attending orientation at two pre-determined community PA facilities (these sites were selected due to each being the largest urban and rural YMCA referral sites in the study)\n\nExclusion criteria:\n\n* Unable to provide verbal informed consent\n* Planning on travel or vacation during data collection, as patient PA behavior is anticipated to differ from 'everyday' PA behavior at home\n* Unable to wear a watch during work hours due to employment restrictions e.g., food service, healthcare, operating heavy machinery\u002Fconstruction, laboratory-based work etc.\n\nIn addition, for patients completing interviews, the additional inclusion\u002Fexclusion criteria apply:\n\nInclusion criteria:\n\n\\- Received an EIMG referral\n\nExclusion criteria:\n\n* Unable to provide verbal informed consent\n* Unable to speak or understand English\n* \\\u003C18 years of age",{"count":519,"type":21},35,[57],"A public health priority exists for the U.S. healthcare sector to integrate physical activity (PA) as a part of the patient care model. This research will provide valuable information on facilitating optimal implementation of a clinic-to-community model that identifies, refers, and enrolls physically inactive patients to community-based PA programs for the prevention and treatment of chronic diseases. Further, this work will provide evidence on the cost-effectiveness of integrating PA in healthcare systems as a population health management strategy.",[523,28,524,86,87,525,526,527,528,446,529],"Physical Inactivity","Obesity and Overweight","Health Care Delivery","Patients","Chronic Disease","Exercise","Implementation Science",[531,532,533,534,535],"Implementation Facilitation","Physical activity referral scheme","Effectiveness-implementation hybrid type 3","Pragmatic design","Stepped wedge","2026-03-27",{"date":538,"type":36},"2026-04-02",{"date":540,"type":21},"2026-05-01",{"date":542,"type":21},"2030-07-31",{"name":544,"class":71},"University of South Carolina",{"id":546,"slug":4,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":11,"sex":16,"minAge":550,"maxAge":551,"enrollmentInfo":552,"targetDuration":4,"studyType":408,"phases":4,"briefSummary":554,"conditions":555,"keywords":556,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":72},"100568041","NCT06676046","Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions","* INCLUSION CRITERIA:\n\nAffected Participants\n\n* Male and female participants age \\>= 10 years.\n* Subjects with confirmed or suspected rare disorder that causes lipid\u002Flipoprotein abnormalities (dyslipidemia) or abnormal documented or referred atherosclerosis patterns.\n* Only affected individuals (not healthy volunteers and for self-referred subjects independent of lipid and lipoprotein marker values.); subjects with laboratory or clinical presentation that in the opinion of the Principal Investigator, would alter the determination of normal\n\nparameters for assays and screening tools development.\n\n-Ability of the subject or Legally Authorized Representative (LAR) to understand and willingness to sign a written informed consent document.\n\nHealthy Volunteers\n\n* Participants must be healthy, with no known history of lipid disorders or related medical conditions.\n* Participants must not be pregnant.\n\nEXCLUSION CRITERIA:\n\n* Patients with disorders that cause common secondary\u002Flipoprotein alterations.\n* Patients with any other findings that, in the opinion of the Principal Investigator, would preclude them from participating in the study.","10 Years","90 Years",{"count":553,"type":21},1500,"Background:\n\nThe right amount of fats in the blood (cholesterol and triglycerides) are a key part of a healthy organism. Too much or too little of these fats may manifest as diseases (dyslipidemia). There are many causes for these abnormalities, but some are genetically determined and we would like to better understand the progression of these conditions over time.\n\nObjective:\n\nThis natural history study aims to learn more about dyslipidemias; how they change over time; and how they respond to therapy. We also want to develop new diagnosis methods for these conditions. With the knowledge we will acquire we hope to provide new insights, new approaches and improve the overall health of these patients.\n\nEligibility:\n\nIndividuals aged 10 years and older, residing both within and outside the United States, who have or are suspected of having a disorder that causes changes in the levels of fats in their blood (genetic dyslipidemias).\n\nDesign:\n\nParticipants residing within and outside the United States will be screened. Their medical records may be reviewed. They may talk to researchers about their medical history by phone, telehealth, or in person.\n\nAll study visits are optional. Participants may visit the NIH up to 15 times per year, if needed.\n\nEach visit may include a physical exam and blood tests. Participants may also have an electrocardiogram (EKG). The EKG measures the electrical activity when the heart beats.\n\nIn some cases, participants may remain in the study for up to 20 years.",[28,147],[557,558,559,560,147,561],"Uncommon Dyslipidemias","Rare Lipid Disorders","Unusual Atherosclerotic Conditions","Lipoproteins","TRIGLYCERIDES","2026-03-20",{"date":564,"type":36},"2026-03-23",{"date":566,"type":36},"2025-01-15",{"date":568,"type":21},"2044-11-24",{"name":570,"class":571},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"id":573,"slug":4,"hasResults":11,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":577,"enrollmentInfo":578,"targetDuration":4,"studyType":408,"phases":4,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":4},"100629559","NCT07476248","The Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes Mellitus","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Diagnosed cases of diabetes mellitus (Type 1 or Type 2), with or without diabetic nephropathy\n* Willingness to participate and provide informed consent\n\nExclusion Criteria:\n\n* Known non-diabetic causes of chronic kidney disease\n* Acute kidney injury\n* Chronic inflammatory or autoimmune diseases\n* Current use of medications known to significantly alter lipid metabolism (other than standard lipid-lowering therapy, if applicable)\n* End-stage renal disease patients on dialysis","80 Years",{"count":579,"type":21},84,"The study aims to examine the relationship between the non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) and CKD in patients with DM.",[582,28],"Diabetic Nephropathy",[584,585,586],"Chronic kidney disease ( CKD )","Diabetes mellitus type 1","Diabetes mellitus type 2","2026-03-12",{"date":589,"type":36},"2026-03-17",{"date":591,"type":21},"2026-10-01",{"date":593,"type":21},"2027-12-01",{"name":595,"class":71},"Assiut University",{"id":597,"slug":4,"hasResults":11,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":22,"phases":605,"briefSummary":606,"conditions":607,"keywords":611,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":72},"100627340","NCT07447362","Clinical Management of Cardiovascular Risk Factors in Adult Patients: A Before-and-After Interventional Study","Effect of a Structured Clinical and Pharmacological Management Strategy on Cardiovascular Risk Factors in Adult Patients in Routine Clinical Practice: A Pseudo-Experimental Before-and-After Study","CV-RISK","Inclusion Criteria:\n\n* Age ≥18 years\n* Presence of at least one cardiovascular risk factor (hypertension, diabetes, dyslipidemia, obesity, or smoking)\n* Receiving outpatient clinical follow-up\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe clinical instability requiring hospitalization\n* Pregnancy\n* End-stage renal disease or dialysis\n* Inability to complete follow-up visits\n* Refusal to participate",{"count":604,"type":21},220,[57],"This study aims to evaluate cardiovascular risk factors, clinical characteristics, and outcomes in adult patients attending an outpatient cardiology clinic. The research focuses on identifying predictors of adverse cardiovascular events, optimizing risk stratification, and improving preventive strategies in routine clinical practice. Data will be collected from patients receiving standard cardiology care without altering their treatment. The results are expected to contribute to better understanding of cardiovascular risk profiles and to support improvements in clinical decision-making and patient management.",[298,86,28,608,441,609,610],"Type 2 Diabetes Mellitus","Overweight","Tobacco Use",[380,612,613,614],"Risk factor control","Medication adherence","Clinical follow-up","2026-02-27",{"date":617,"type":36},"2026-03-03",{"date":619,"type":36},"2024-07-24",{"date":621,"type":21},"2026-10-24",{"name":623,"class":71},"Universidad Católica San Antonio de Murcia",{"id":625,"slug":4,"hasResults":11,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":408,"phases":4,"briefSummary":632,"conditions":633,"keywords":638,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":72},"100624655","NCT07412457","Guideline Adherence in Dyslipidemia With Clinical Decision Support","Assessment of Adherence to Clinical Practice Guidelines in Patients With Dyslipidemia Using a Clinical Decision Support System","Inclusion Criteria:\n\n1. Availability of the required amount of patient data for completion of the questionnaire-based system;\n2. Age 18 years or older;\n3. Signed informed consent to participate in the study.\n\nNon-inclusion criteria:\n\n1. Patients with insufficient data to complete the questionnaire;\n2. Refusal to sign informed consent for participation in the study.\n\n   Exclusion Criteria:\n3. Absence of a consensus opinion on the clinical case among two of the three experts.",{"count":631,"type":21},500,"Objective: To validate the performance of the developed clinical decision support system (CDSS) for participants with lipid metabolism disorders based on a decision tree algorithm.\n\nMaterials and Methods: A clinical decision support system for participants with lipid profile abnormalities will be developed using the Orbeon open-source online form creation platform based on current clinical guidelines.\n\nDuring the CDSS pilot implementation, the electronic medical records (EMRs) of 500 participants from the Institute of Personalized Cardiology of the Biomedical Science and Technology Park at Sechenov University will be analyzed.\n\nRetrospective data on prescribed lipid-lowering therapy extracted from the EHR will be compared with the CDSS recommendations. The accuracy of the decisions will be assessed by three independent experts based on digitized clinical and laboratory patient profiles.\n\nThe primary endpoint of the study will be to determine the accuracy of the system.\n\nResults: This study will result in the development (creation) and pilot application of the CDSS program in participants with dyslipidemia in real clinical practice.\n\nConclusion: The developed CDSS system for dyslipidemia will significantly reduce the time required for clinical decision-making and help avoid errors in the interpretation of patient data.",[28,634,635,636,637],"Coronary Artery Disease","Atherosclerosis of Major Arteries","Cardiovascular Risk","Subclinical Atherosclerosis",[639,640,641,418],"dyslipidemia","atherosclerosis","revascularization","2026-02-22",{"date":644,"type":36},"2026-02-24",{"date":646,"type":21},"2026-04-01",{"date":648,"type":21},"2027-09-30",{"name":650,"class":71},"I.M. Sechenov First Moscow State Medical University",{"id":652,"slug":4,"hasResults":11,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":22,"phases":658,"briefSummary":659,"conditions":660,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":72},"100623775","NCT07401017","The Effects of Rosuvastatin on Running Training Adaptation and Safety","The Effects of Rosuvastatin on Physiological Adaptation and Safety During Regular Long-Distance Running Training: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Meets clinical criteria for statin therapy, including at least one of the following:\n* Family history of hyperlipidemia.\n* LDL-C ≥ 160 mg\u002FdL.\n* 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk ≥ 7.5%\n* Diabetes mellitus with LDL-C ≥ 70 mg\u002FdL.\n* Determined by a clinician to require lipid-lowering therapy.\n* Currently using or eligible to initiate rosuvastatin therapy.\n* Performs long-distance running at least 3 times per week and is willing to maintain regular training for 3 months.\n* Able and willing to undergo cardiopulmonary exercise testing (CPET) and to record training data using a sports watch (for TRIMP calculation).\n* No known drug allergies and provides written informed consent after study explanation.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to statins or rosuvastatin.\n* History of severe statin-related adverse events, including rhabdomyolysis or marked creatine kinase (CK) elevation.\n* Liver dysfunction with AST or ALT \\> 3× upper limit of normal.\n* Moderate to severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n* Current lower-limb pain, tendon injury, or other conditions that prevent running training.\n* Not suitable for maximal cardiopulmonary exercise testing (CPET), such as unstable angina, uncontrolled hypertension, or recent cardiovascular events.\n* Pregnant or breastfeeding.\n* Inability to comply with study procedures, including use of a sports watch, regular follow-up visits, or maintaining running training.",{"count":469,"type":21},[57],"Statins lower low-density lipoprotein cholesterol (LDL-C) and help prevent atherosclerotic cardiovascular disease, but some users develop statin-associated muscle symptoms (SAMS) such as soreness, stiffness, weakness, or elevated creatine kinase (CK). These symptoms may be more noticeable during exercise. Regular long-distance running improves cardiopulmonary fitness-VO₂max, aerobic threshold (AT), and respiratory compensation point (RCP)-mainly through mitochondrial and metabolic adaptations. Prior studies suggest that lipophilic statins like simvastatin may blunt these adaptations, while hydrophilic statins such as rosuvastatin may have a smaller impact. However, prospective data in habitual endurance runners are limited.\n\nThis randomized controlled trial will examine how rosuvastatin affects cardiopulmonary fitness improvements and muscle tolerance in individuals who run at least three times per week and meet clinical criteria for statin therapy. After informed consent and baseline cardiopulmonary exercise testing (CPET), participants will be randomized to rosuvastatin 10 mg daily or no statin therapy for three months. Both groups will maintain their usual training routines, and training load will be recorded using heart-rate-based TRIMP. CPET will be repeated monthly to assess changes in VO₂max, AT, and RCP, and muscle enzymes and SAMS will be evaluated at each visit.\n\nThe study aims to clarify whether rosuvastatin influences endurance-related physiological adaptations or increases muscle symptoms in regular long-distance runners.",[28,661,662,663],"Long-Distance Running","Endurance Training","Statin-Associated Muscle Symptoms","2026-02-05",{"date":666,"type":36},"2026-02-10",{"date":668,"type":21},"2026-03-01",{"date":670,"type":21},"2026-10-31",{"name":672,"class":71},"Taipei Medical University WanFang Hospital",""]